About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Active Pharmaceutical Ingredients CDMO Market Size Report to 2033
Active Pharmaceutical Ingredients CDMO Market

Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Antibody Drug Conjugate, Others), By Synthesis (Synthetic, Biotech), By Drug (Innovative, Generics), By Applications (Oncology, Hormonal, Glaucoma, Cardiovascular Disease, Diabetes, Others), By Workflow (Clinical, Commercial) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI54097DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Active Pharmaceutical Ingredients CDMO Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Traditional API
        1. By Value
      3. HP-API
        1. By Value
      4. Antibody Drug Conjugate
        1. By Value
      5. Others
        1. By Value
    3. By Synthesis
      1. Introduction
        1. Synthesis By Value
      2. Synthetic
        1. By Value
      3. Biotech
        1. By Value
    4. By Drug
      1. Introduction
        1. Drug By Value
      2. Innovative
        1. By Value
      3. Generics
        1. By Value
    5. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Cardiovascular Disease
        1. By Value
      6. Diabetes
        1. By Value
      7. Others
        1. By Value
    6. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Clinical
        1. By Value
      3. Commercial
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Traditional API
        1. By Value
      3. HP-API
        1. By Value
      4. Antibody Drug Conjugate
        1. By Value
      5. Others
        1. By Value
    3. By Synthesis
      1. Introduction
        1. Synthesis By Value
      2. Synthetic
        1. By Value
      3. Biotech
        1. By Value
    4. By Drug
      1. Introduction
        1. Drug By Value
      2. Innovative
        1. By Value
      3. Generics
        1. By Value
    5. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Cardiovascular Disease
        1. By Value
      6. Diabetes
        1. By Value
      7. Others
        1. By Value
    6. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Clinical
        1. By Value
      3. Commercial
        1. By Value
    7. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Traditional API
          1. By Value
        3. HP-API
          1. By Value
        4. Antibody Drug Conjugate
          1. By Value
        5. Others
          1. By Value
      2. By Synthesis
        1. Introduction
          1. Synthesis By Value
        2. Synthetic
          1. By Value
        3. Biotech
          1. By Value
      3. By Drug
        1. Introduction
          1. Drug By Value
        2. Innovative
          1. By Value
        3. Generics
          1. By Value
      4. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Cardiovascular Disease
          1. By Value
        6. Diabetes
          1. By Value
        7. Others
          1. By Value
      5. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Clinical
          1. By Value
        3. Commercial
          1. By Value
    8. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Traditional API
        1. By Value
      3. HP-API
        1. By Value
      4. Antibody Drug Conjugate
        1. By Value
      5. Others
        1. By Value
    3. By Synthesis
      1. Introduction
        1. Synthesis By Value
      2. Synthetic
        1. By Value
      3. Biotech
        1. By Value
    4. By Drug
      1. Introduction
        1. Drug By Value
      2. Innovative
        1. By Value
      3. Generics
        1. By Value
    5. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Cardiovascular Disease
        1. By Value
      6. Diabetes
        1. By Value
      7. Others
        1. By Value
    6. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Clinical
        1. By Value
      3. Commercial
        1. By Value
    7. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Traditional API
          1. By Value
        3. HP-API
          1. By Value
        4. Antibody Drug Conjugate
          1. By Value
        5. Others
          1. By Value
      2. By Synthesis
        1. Introduction
          1. Synthesis By Value
        2. Synthetic
          1. By Value
        3. Biotech
          1. By Value
      3. By Drug
        1. Introduction
          1. Drug By Value
        2. Innovative
          1. By Value
        3. Generics
          1. By Value
      4. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Cardiovascular Disease
          1. By Value
        6. Diabetes
          1. By Value
        7. Others
          1. By Value
      5. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Clinical
          1. By Value
        3. Commercial
          1. By Value
    8. Germany
    9. France
    10. Spain
    11. Italy
    12. Russia
    13. Nordic
    14. Benelux
    15. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Traditional API
        1. By Value
      3. HP-API
        1. By Value
      4. Antibody Drug Conjugate
        1. By Value
      5. Others
        1. By Value
    3. By Synthesis
      1. Introduction
        1. Synthesis By Value
      2. Synthetic
        1. By Value
      3. Biotech
        1. By Value
    4. By Drug
      1. Introduction
        1. Drug By Value
      2. Innovative
        1. By Value
      3. Generics
        1. By Value
    5. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Cardiovascular Disease
        1. By Value
      6. Diabetes
        1. By Value
      7. Others
        1. By Value
    6. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Clinical
        1. By Value
      3. Commercial
        1. By Value
    7. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Traditional API
          1. By Value
        3. HP-API
          1. By Value
        4. Antibody Drug Conjugate
          1. By Value
        5. Others
          1. By Value
      2. By Synthesis
        1. Introduction
          1. Synthesis By Value
        2. Synthetic
          1. By Value
        3. Biotech
          1. By Value
      3. By Drug
        1. Introduction
          1. Drug By Value
        2. Innovative
          1. By Value
        3. Generics
          1. By Value
      4. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Cardiovascular Disease
          1. By Value
        6. Diabetes
          1. By Value
        7. Others
          1. By Value
      5. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Clinical
          1. By Value
        3. Commercial
          1. By Value
    8. Korea
    9. Japan
    10. India
    11. Australia
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Traditional API
        1. By Value
      3. HP-API
        1. By Value
      4. Antibody Drug Conjugate
        1. By Value
      5. Others
        1. By Value
    3. By Synthesis
      1. Introduction
        1. Synthesis By Value
      2. Synthetic
        1. By Value
      3. Biotech
        1. By Value
    4. By Drug
      1. Introduction
        1. Drug By Value
      2. Innovative
        1. By Value
      3. Generics
        1. By Value
    5. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Cardiovascular Disease
        1. By Value
      6. Diabetes
        1. By Value
      7. Others
        1. By Value
    6. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Clinical
        1. By Value
      3. Commercial
        1. By Value
    7. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Traditional API
          1. By Value
        3. HP-API
          1. By Value
        4. Antibody Drug Conjugate
          1. By Value
        5. Others
          1. By Value
      2. By Synthesis
        1. Introduction
          1. Synthesis By Value
        2. Synthetic
          1. By Value
        3. Biotech
          1. By Value
      3. By Drug
        1. Introduction
          1. Drug By Value
        2. Innovative
          1. By Value
        3. Generics
          1. By Value
      4. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Cardiovascular Disease
          1. By Value
        6. Diabetes
          1. By Value
        7. Others
          1. By Value
      5. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Clinical
          1. By Value
        3. Commercial
          1. By Value
    8. Turkey
    9. Saudi Arabia
    10. South Africa
    11. Egypt
    12. Nigeria
    13. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Traditional API
        1. By Value
      3. HP-API
        1. By Value
      4. Antibody Drug Conjugate
        1. By Value
      5. Others
        1. By Value
    3. By Synthesis
      1. Introduction
        1. Synthesis By Value
      2. Synthetic
        1. By Value
      3. Biotech
        1. By Value
    4. By Drug
      1. Introduction
        1. Drug By Value
      2. Innovative
        1. By Value
      3. Generics
        1. By Value
    5. By Applications
      1. Introduction
        1. Applications By Value
      2. Oncology
        1. By Value
      3. Hormonal
        1. By Value
      4. Glaucoma
        1. By Value
      5. Cardiovascular Disease
        1. By Value
      6. Diabetes
        1. By Value
      7. Others
        1. By Value
    6. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Clinical
        1. By Value
      3. Commercial
        1. By Value
    7. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Traditional API
          1. By Value
        3. HP-API
          1. By Value
        4. Antibody Drug Conjugate
          1. By Value
        5. Others
          1. By Value
      2. By Synthesis
        1. Introduction
          1. Synthesis By Value
        2. Synthetic
          1. By Value
        3. Biotech
          1. By Value
      3. By Drug
        1. Introduction
          1. Drug By Value
        2. Innovative
          1. By Value
        3. Generics
          1. By Value
      4. By Applications
        1. Introduction
          1. Applications By Value
        2. Oncology
          1. By Value
        3. Hormonal
          1. By Value
        4. Glaucoma
          1. By Value
        5. Cardiovascular Disease
          1. By Value
        6. Diabetes
          1. By Value
        7. Others
          1. By Value
      5. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Clinical
          1. By Value
        3. Commercial
          1. By Value
    8. Mexico
    9. Argentina
    10. Chile
    11. Colombia
    12. Rest of LATAM
    1. Active Pharmaceutical Ingredients CDMO Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Cambrex Corporation
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Recipharm AB
    3. Thermo Fisher Scientific Inc. (Pantheon)
    4. Corden Pharma International
    5. Samsung Biologics
    6. Lonza Group
    7. Catalent, Inc.
    8. Siegfried Holding AG
    9. Piramal Pharma Solutions
    10. Boehringer Ingelheim
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global active pharmaceutical ingredients (API) market size was valued at USD 209.19 million in 2022. It is expected to reach USD 487.01 million by 2031, growing at a CAGR of 6.05% during the forecast period (2023–2031). Any substance or co
Buy Now
Global Report
The global high potency active pharmaceutical ingredients market size was valued at USD 24.782 billion in 2022. It is estimated to reach USD 48.53 billion by 2031, growing at a CAGR of 9.37% during the forecast period (2023–2031). High Po
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.